• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Solid organ transplantations and COVID-19 disease

    2021-12-21 08:29:28EmineAylinlmaznerzdemir
    World Journal of Transplantation 2021年12期

    Emine Aylin Y?lmaz, ?ner ?zdemir

    Emine Aylin Y?lmaz, ?ner ?zdemir, Division of Pediatric Allergy and Immunology, Sakarya University Medical Faculty, Adapazar? 54100, Sakarya, Turkey

    Abstract Tens of thousands of people worldwide became infected with syndrome coronavirus-2 (SARS-CoV-2). Death rate in general population is about 1%-6%, but this rate rises up to 15% in those with comorbidities. Recent publications showed that the clinical progression of this disease in organ recipients is more destructive, with a fatality rate of up to 14%-25%. We aimed to review the effect of pandemic on various transplantation patients. coronavirus disease 2019 (COVID-19) has not only interrupted waiting list patients’ lives; it has also impacted transplantation strategies, transplant surgeries and broke donation chains. COVID-19 was directly and indirectly accountable for 73% surplus in mortality of this population as compared to wait listed patients in earlier years. The impact of chronic immunosuppression on outcomes of COVID-19 remains unclear but understanding the immunological mechanisms related to the virus is critically important for the lifetime of transplantation and immune suppressed patients. It is hard to endorse changing anti-rejection therapy, as the existing data appraised is not adequate to advise substituting tacrolimus with cyclosporine during severe COVID-19 disease.

    Key Words: COVID-19; SARS-CoV-2; Solid organ transplantation

    INTRODUCTION

    Introduction and aim

    Tens of thousands of people worldwide became infected with syndrome coronavirus-2 (SARS-CoV-2)[1]. When the disease is clinically symptomatic; it presents with fever, cough, lymphopenia, dyspnea and, multiorgan failure in severe cases[2]. Death rate in general population is about 1%-6%, but this rate rises up to 15% in those with comorbidities[3]. Current publications showed that the clinical progression of this disease in organ recipients is more destructive, with a fatality rate of up to 14%-25%. We aimed to review the effect of pandemic on various transplantation patients[4].

    Negative effects of coronavirus disease 2019 in increasing waiting list of organ transplantations

    Coronavirus disease 2019 (COVID-19) has not only interrupted waiting list patients’ lives; it has also affected transplantation strategies, transplant surgeries and broke donation chains. COVID-19 was directly and indirectly accountable for 73% surplus in mortality of this population as compared to wait listed patients in former years[5].

    High COVID-19 afflicted areas observed more than 2.2 times bigger waiting list fatality as compared to prepandemic mortality in the United States[6]. In the United Kingdom, 10% of wait listed patients who developed COVID-19 died[7]. In France, as many as 42% of wait listed deaths in March and April 2020 were caused by COVID-19[5].

    Kidney transplant waiting list deaths increased by 43%, largest in any solid organ transplanted patient group on the waiting list[8,9]. In perspective, there was a 12% increase in deaths in patients on the lung transplant waiting list, an 8% increase in deaths on a liver transplant waiting list, and a 36% increase in deaths in patients on a heart transplant waiting list[10].

    Transplant and waiting list patients have similar death rates after admitted to the hospital for COVID-19 disease. A study has demonstrated a low absolute fatality risk from COVID-19 in transplanted and waitlisted cases, but a high and similar death rate when admitted to hospital, of around 30%. Death rate was higher in elderly transplant recipient cases[11].

    UNDESIRABLE EFFECTS OF IMMUNOSUPPRESSION ON COVID-19 IN TRANSPLANTATION PATIENTS

    The impact of chronic immunosuppression on outcomes of COVID-19 remains unclear but understanding the immunological mechanisms related to the virus is critically important for the lifetime of transplantation and immune suppressed patients.

    Given the reduced T-cell immunity, transplant recipients estimated to be at greater risk for serious bacterial and viral infections. The difficult problem is coronavirusinfected immunosuppressed and SOT patients who is taking whether intravenous immunoglobulin (IVIG), steroids, calcineurin inhibitors or mycophenolic acid. Solid organ transplantation itself covers various clinical conditions/issues resulting from kidney, liver, heart and lung transplantations (Table 1).

    Table 1 Therapeutic agents used during solid organ transplantation period and their side effects

    Angiotensin-converting enzyme-2 and dipeptidyl peptidase, expressed in proximal tubular cells, are identified as receptors for SARS-CoV and MERS-CoV[12]. The possible explanation for acute renal injury is the uptake of SARS-CoV-2 virus into the proximal tubular epithelium and virus infection inducing CD68+ -macrophage infiltration and enhancing complement C5b-C9 deposition on tubules[13].

    Acute renal injury is one of the commonest complications of COVID-19. It was seen in 30%-89% of patients with kidney transplantation. Acute renal injury has developed as a result of many factors like decreased renal perfusion and cytokine storm[14]. To date, minimizing the utilization of antivirals and immunosuppressive therapy has been recommended, but the evidence has been weak to support these recommendations[1]. Hypothetical, conversion to cyclosporine, in kidney transplant patients with COVID-19 has both antiviral potency and immunomodulatory effects; it may also help to avoid graft rejection during the infection[1].

    Several studies have reported that immunosuppression may be a possible risk factor for coronavirus-related pneumonia in a patient[13]. For kidney transplant recipients diagnosed with SARS-CoV-2, it may be reasonable to use cyclosporine because of its antiviral and immune modulatory effects[13]. According to various clinical studies, severe pneumonia has been more widely reported in patients receiving anti-rejection and induction therapies, possibly due to immunosuppression[15].

    The management of heart transplant recipients becomes more complex as these heart transplant patients require more intense immunosuppression than other SOT recipients[16]. In addition to the present complexity, COVID-19 have a potential effect on both primary and secondary myocardial injuries[17]. These cases are constantly utilizing long-term immunosuppressive therapy and at a high risk to develop unwanted effects. Although they have adequate heart function, this population must be thought as very brittle owing to the existence of several comorbidities like chronic renal disease associated with a long exposure to immunosuppressants. In a transplanted cases’ cohort, time-dependent comorbidities along with older age, such as calcineurin inhibitor nephrotoxicity and other common complications of immunosuppressive management, could also be harmful[18].

    Transplant recipients are thought by some authors as a high-risk group for COVID-19 since they take lifetime immunosuppressive treatment. Immunomodulatory agents could improve immune reaction, but this could yield to an escalation in viral load and postponed disease salvage. Remarkably, calcineurin inhibitors, the most commonly used immunosuppressive agent in lung transplant recipients, have shown impressive capacities to inhibit the replication of coronaviruses. Therefore, it was suggested that basic immunomodulation could defend lung transplant patients against the most severe clinical pictures of COVID-19 disease[19].

    Calcineurin inhibitors, antimetabolites, and glucocorticosteroids are the most commonly used as standard immunosuppressants; nonetheless, in COVID-19 confirmed patients, antimetabolites were generally stopped while prescription of glucocorticosteroids was continued in management or even amplified in dosage. It was thought as essential to use suitable doses of glucocorticosteroids through the process, as it could subdue hyperinflammatory reaction and stimulate the recovery from pneumonia without severe unwanted effects[20].

    Impact of co-infections (fungal) with COVID-19 in transplantation patients

    Impact of co-infections (bacterial or viral) with COVID-19 disease in SOT patients could be severe and mortal. To the best of our knowledge, specific co-infections (bacterial or viral) related with SARS-CoV-2 in SOT patients have not been reported much. However, SARS-CoV-2 might rise the risk of invasive pulmonary aspergillosis (?PA) development in these patients. Although several case reports and small series have been described in the literature, infrequent information is obtainable concerning COVID-19-related ?PA in SOT cases. A case of a renal SOT recipient with severe COVID-19 was later diagnosed with IPA. After beginning of isavuconazole with nebulized liposomal amphotericin B combination treatment and the withdrawal of immunosuppression, ?PA was improved[21].

    Other risk factors for COVID-19 development and mortality in transplantation patients

    SOT cases with COVID-19 had a tendency to greater mortality compared with non-SOT controls, although it was not always found to be statistically significant[20,22]. Immunosuppression and comorbidities might put SOT patients at upper risk from COVID-19, as proposed by new case series[23]. In the overall literature, some factors were shown to be independently related with COVID-19 included non-white race and comorbidities, comprising obesity, diabetes, asthma and chronic obstructive pulmonary disease[24]. Nevertheless, no factors were demonstrated to be related with fatality, other than being elderly in those who had been transplanted in the literature[11].

    A few studies have clearly compared consequences between SOT and non-SOT patients with COVID-19 disease. A retrospective matched cohort single-center study evaluated effects of COVID-19 and the effect of immunomodulation on cytokine release syndrome of COVID-19 in SOT patients. Overall, SOT recipient cases had equal fatality to non-SOT cases, although more SOT cases received tocilizumab (63%vs48%) and steroids (37%vs20%)[25]. In another study, 45 SOTvs2427 non-SOT cases hospitalized with COVID-19 to a health-care system were compared. There were no statistically meaningful differences between SOT and non-SOT in maximum illness severity score, length-of- stay, or mortality. Regardless of a greater risk profile, SOT recipients had a significantly faster drop in disease severity over time compared with non-SOT cases[23]. Chaudhryet al[26] compared consequences of 35 SOT cases with 100 non-SOT cases that were admitted with COVID-19 at a single center, and detected that a combined consequence [intensive care units (ICU) admission, intubation, hospital fatality] was similar between these 2 groups, even though comorbidities and acute renal damage were more usual in the SOT case group[26]. Generally, SOT cases were more likely to take COVID-19 specific treatments and to need ICU admission. However, fatality (23.08% in SOTvs23.14% in non-SOT) and highest level of supplementary oxygen needed during admission did not significantly vary between these groups[27].

    As a result from overall literature, mortality in SOT recipients compared to controls (non-SOT patients) has been detected as similar and the SOT programs should not be stopped and are better to be continued.

    VARIOUS THERAPEUTIC OPTIONS OF COVID-19 DISEASE IN TRANSPLANTED PATIENTS

    Convalescent immune plasma (CIP) infusion has been utilized in the therapy of other infectious diseases for more than a century[28], under the notion that passive immunization can push the immune system to prevent the disease progression until a specific immune response is developed in the afflicted person[29]. However, the use of CIP did not improve survival in non-transplant patients with severe COVID-19 disease[29]. According to a randomized control trials study at day 30, no significant difference was reported between the CIP and the placebo groups[29].

    A course of IVIG at dose of 1 g/kg was given as an immunomodulatory therapy in patients with serum immunoglobulin G (IgG) level < 700 mg/dL. Antiviral treatment was not administered in any group. According to a large, randomized open-label trial, dexamethasone was related with lower fatality in patients necessitating mechanical ventilation or supplemental oxygen, compared with a standard care[30].

    Mycophenolate has a cytostatic effect on activated lymphocytes. In COVID-19, the virus SARS-CoV-2 has a direct cytotoxic effect on CD8+ -lymphocytes, thus explaining the relation between lymphopenia and poorer outcomes. Consequently, mycophen- olate and SARS-CoV-2 may reveal a synergic and side effect on diminishing peripheral lymphocytes, which would be accountable for a deviant immune modification as shown with other viruses. On the contrary, mechanistic target of rapamycin (mTOR) inhibitors enhance the quality and functionality of memory T-cells and lessen the replication of numerous viruses[31].

    Cyclosporine can be beneficial at any moment through the progress of the disease given its impact on the inhibition of viral replication, maintenance of renal graft and down regulation of the immune reaction. Cyclosporine and tacrolimus are the most utilized calcineurin inhibitors in regular clinical practice for inhibition of alloimmune response in transplantation. Calcineurin inhibitors subdue the immune system and the primary action is inhibition of interleukin-2 (IL-2) production in T-cells. Cyclosporine and tacrolimus are chemically different molecules. Calcineurin inhibitors attach to intracellular cyclophilin, which is an immunophilin, and this calcineurin inhibitorimmunophilin complex inhibits nuclear factor of activated T-cells (NFAT). As a result of NFAT inhibition, cytokine transcription and T-cell activation are blocked[32]. The cyclosporine level needed to prevent virus replication surpasses by far the serum levels that characteristically are well below 200 ng/mL[32]. This indicates that the dose utilized to manage most patients with cyclosporine is too low to successfully eliminate the virus. One of the issues is to reach adequate tissue level, as the key virus load is in the respiratory tract and lungs rather than in serum and the cyclosporine concentration in the lungs is lesser than in serum[32]. Additionally, the necessary dosage for vigorously treating severe COVID-19 patients would be 3-6 times greater, which in turn would trigger severe adverse and possible toxic effects, specifically nephrotoxicity[32]. Inhaled cyclosporine has been tried in animals, healthy volunteers and pulmonary transplantation recipients and the pulmonary amount of inhaled cyclosporine is three times more than when systemically administered[32].

    Calcineurin inhibitors, such as cyclosporine A and tacrolimus, have a significant role in continuing immunosuppression after SOT. Those medications have a slight therapeutic window, and individual doses and drug management watching are required. A significant amount of cases suffer from short- or long-term calcineurin inhibitors toxicity, with renal dysfunction, hypertension, neurotoxicity and metabolic instabilities[33]. Dose minimization is related with a modest improvement in kidney function, but persistent injury is detected on biopsies if the calcineurin inhibitors are sustained. Calcineurin inhibitor cessation may be the best option by providing calcineurin inhibitors through the early period of immunologic graft damage and then changing them to less nephrotoxic drugs before imperative renal damage happens[34].

    Prophylactic lessening of immunosuppression due to fear of COVID-19 disease is not recommended in SOT recipients. With maintenance immunosuppressive management, glucocorticosteroids can be sustained during COVID-19 disease[35]. Sustaining other immunosuppressive medications with lowest effective dose/blood concentration is recommended for cases having mild to moderate COVID-19. Withdrawal of antimetabolitese.g.mycophenolate mofetil and maybe inhibitors of mTOR such as sirolimus is recommended in moderate to severe COVID-19. Calcineurin inhibitors may be sustained or replaced for mTOR inhibitors with lowermost therapeutic levels in moderate to severe COVID-19. If sustained in COVID-19 cases, therapeutic drug watching of calcineurin/mTOR inhibitors and proper dose lessening is suggested in combination with protease inhibitors, hydroxychloroquine/chloroquine, or IL-1/IL-6 receptor antagonists. Checking hemogram is suggested in cases using antimetabolite drugs or mTOR inhibitors. Drug dose adjustment/evasion should be thought for chloroquine, atazanavir, oseltamivir, ribavirin, anakinra, and Janus associated kinase (Jak) inhibitors in cases with organ dysfunctions[36].

    Anti-COVID-19 medicationse.g.lopinavir/ritonavir and hydroxychloroquine have not been tried by laborious clinical trials. These medications may be utilized cautiously for common patients with COVID-19, but for SOT recipients using long-term immunosuppressive management, antiviral medications should be meticulously chosen. Moreover, the senior SOT patients frequently afflicted with hepatic and renal dysfunction of varying degrees, resulting in worse drug metabolism. The combination of lopinavir/ritonavir and hydroxychloroquine is blamable for extreme tacrolimus trough level with unwanted effects[37].

    COVID-19 VACCINATION IN TRANSPLANTATION PATIENTS

    In transplant recipient patients, the COVID-19 vaccine is a way to protect these patients when there is no definitive cure for COVID-19. On waiting list of cases with COVID-19, serologic studies have showed that IgM levels increase 5–10 d after infection onset. IgG development classically follows an IgM response development within 12–14 d of symptom onset in most patients[9]. Follow-up studies suggest that these responses last for at least 5 months succeeding infection and can confer immunity against repeated SARS-CoV-2 infections[9].

    Growing evidence indicates that SOT recipients who take mRNA-based vaccines have low immunization rates[38]. Less than half of the vaccinated transplant cases demonstrated antibodies against the SARS-CoV-2 spike protein[38]. Although immunosuppressant agents are thought to have a key role during this course, the appearance of severe COVID-19 disease after mRNA-based vaccination in immunocompetent or immunocompromised individuals has not yet been described[38]. A possible reason for this might owe to lack of humoral response, together with a restricted or deficient T-cell response, even after the second dose of the vaccination[38]. Live (replication-competent) vaccines are usually contraindicated in immunocompromised subjects due to a risk of vaccine-acquired disease[39]. These vaccines contain intact virions that are engineered to incorporate the gene encoding the SARS-CoV-2 spike protein, somehow influences the viral vector’s capacity to competently infect cells and increases spike gene delivery[39]. It should be emphasized that immunosuppression isn’t considered as a contraindication to their use, despite the theoretical concerns with replication-deficient viral vector-based vaccines. SARS-CoV-2 vaccines have significant potential to decrease COVID-19-associated morbidity and mortality among recipients of SOT, including kidney transplants[39].

    In a study, 14 SOT recipients were diagnosed with COVID-19 after 24 d from application of vaccines. One patient deceased, 2 patients were hospitalized and 11 patients were improved at home. 50% of infected cases were hospitalized for the management. There was enough data to issue warnings that immunologically incompetent people should remain to practice firm COVID-19 precautions after vaccination and direction given to the overall people may not be relevant to the SOT patients[40].

    SOME ISSUES OF TRANSPLANTATION PATIENTS DURING COVID-19 PANDEMIC

    As access to hospitals becomes easier; the determination of SARS-CoV-2 infected patients with mild symptoms which would otherwise to be missed in the overall population is increasing.

    Fatality rates were lesser than those detected in the age- and gender-matched common population, thereby signifying that chronic immunosuppression could result in a certain protective effect against the most severe types of COVID-19. According to a multi-center study in Istanbul, the usage of cyclosporine was related with lesser incidence of fatality. On the contrary, rejection treatment was recognized as a risk factor for mortality[15]. Nevertheless, in cases taking mycophenolate, dose lessening, or temporary change to calcineurin inhibitors or everolimus may be thought until complete rescue from COVID-19[31].

    It is hard to endorse changing anti-rejection therapy, as the existing data appraised is not adequate to endorse substituting tacrolimus with cyclosporine during severe COVID-19 disease[32]. Nonetheless, revised guidelines should advise to continue cyclosporine use to the cases during COVID-19 except in some of patients having like kidney failure, severe leucopenia or increased serum cyclosporine levels. A change from tacrolimus to cyclosporine would be founded only on affirmative observational documents with a supposed advantage for COVID-19 illness, but with a likely greater risk of refusal and controlled studies are necessary to exam whether this change is suitable or not[32]. We need to identify which solid organ transplant recipients profit from specific therapies, the ideal timing of these therapies and the balance of benefits and risks of these therapies, such as late secondary infections. We have to embolden clinical trials and observational researches in the future to incorporate solid organ transplant recipients. Long-term follow up of solid organ transplant recipients will be important in order to clarify for these guidelines. For the safety of recipients, testing donors for SARS-CoV-2 has become a cornerstone of kidney transplant practice[9].

    CONCLUSION

    Although negative effects of COVID-19 on increasing waiting list and undesirable effects of immunosuppression on COVID-19 disease in SOT patients; the literature data support continuation of transplant programs during the COVID-19 era[11].

    亚洲 国产 在线| 黄片播放在线免费| 亚洲五月色婷婷综合| 高清毛片免费观看视频网站 | 美女高潮喷水抽搐中文字幕| 国产成人精品久久二区二区免费| 久久久国产成人免费| 久久精品国产亚洲av香蕉五月 | 成人黄色视频免费在线看| h视频一区二区三区| 国产精品熟女久久久久浪| 精品国产一区二区久久| a级片在线免费高清观看视频| av免费在线观看网站| 99久久国产精品久久久| 国产午夜精品久久久久久| 在线观看www视频免费| www.熟女人妻精品国产| 一二三四在线观看免费中文在| 久久毛片免费看一区二区三区| 亚洲色图综合在线观看| 极品人妻少妇av视频| 国产一区二区激情短视频| 老司机靠b影院| 最新美女视频免费是黄的| 午夜福利在线观看吧| 亚洲伊人色综图| 国产视频一区二区在线看| 成年版毛片免费区| 欧美精品啪啪一区二区三区| 最黄视频免费看| 久久精品熟女亚洲av麻豆精品| 女性被躁到高潮视频| 久久久精品94久久精品| 黄频高清免费视频| 色在线成人网| 亚洲中文日韩欧美视频| 十分钟在线观看高清视频www| 亚洲中文av在线| 亚洲美女黄片视频| 欧美激情久久久久久爽电影 | 丁香六月天网| 少妇猛男粗大的猛烈进出视频| 免费观看av网站的网址| 久久狼人影院| 国产成人系列免费观看| 怎么达到女性高潮| 久久久久视频综合| 国产成人影院久久av| 亚洲av美国av| 欧美精品啪啪一区二区三区| 精品午夜福利视频在线观看一区 | 久久99一区二区三区| 久久精品国产亚洲av香蕉五月 | 啦啦啦中文免费视频观看日本| 69精品国产乱码久久久| 天天添夜夜摸| 丝瓜视频免费看黄片| 超碰成人久久| 成年女人毛片免费观看观看9 | 五月天丁香电影| 精品第一国产精品| 久久精品成人免费网站| 久久中文看片网| 国产亚洲av高清不卡| 亚洲免费av在线视频| 免费观看a级毛片全部| 精品国产一区二区三区久久久樱花| 欧美在线黄色| 午夜精品国产一区二区电影| 侵犯人妻中文字幕一二三四区| xxxhd国产人妻xxx| 精品国产一区二区久久| 一区二区三区激情视频| av电影中文网址| 91大片在线观看| 国产精品亚洲av一区麻豆| 波多野结衣一区麻豆| 国产精品欧美亚洲77777| 亚洲成av片中文字幕在线观看| 午夜免费鲁丝| 男女下面插进去视频免费观看| 国产深夜福利视频在线观看| 精品第一国产精品| 99香蕉大伊视频| 国产福利在线免费观看视频| 黑丝袜美女国产一区| 亚洲熟妇熟女久久| 日韩视频在线欧美| 亚洲欧美色中文字幕在线| 97在线人人人人妻| 亚洲精品在线观看二区| 999久久久精品免费观看国产| 男男h啪啪无遮挡| 窝窝影院91人妻| 淫妇啪啪啪对白视频| 欧美日韩亚洲国产一区二区在线观看 | 久久久国产欧美日韩av| 一边摸一边做爽爽视频免费| 精品卡一卡二卡四卡免费| 欧美精品av麻豆av| 亚洲综合色网址| 中文字幕色久视频| 国产成人一区二区三区免费视频网站| 免费人妻精品一区二区三区视频| 久久精品国产亚洲av高清一级| 免费观看av网站的网址| 天天躁狠狠躁夜夜躁狠狠躁| 国产精品影院久久| 黄色怎么调成土黄色| 我要看黄色一级片免费的| 另类精品久久| 成年动漫av网址| 日韩欧美免费精品| 亚洲精品自拍成人| 日韩中文字幕视频在线看片| 国产激情久久老熟女| 午夜日韩欧美国产| 亚洲国产欧美日韩在线播放| 国产在线观看jvid| 人妻一区二区av| 天天添夜夜摸| 麻豆国产av国片精品| av片东京热男人的天堂| 国产成人欧美在线观看 | 亚洲欧美一区二区三区黑人| 99在线人妻在线中文字幕 | 考比视频在线观看| 午夜福利,免费看| 国产精品.久久久| 国产福利在线免费观看视频| 欧美亚洲 丝袜 人妻 在线| 99riav亚洲国产免费| 狠狠狠狠99中文字幕| 国产一区二区三区在线臀色熟女 | 少妇粗大呻吟视频| 黄色视频,在线免费观看| 一进一出好大好爽视频| 欧美日韩中文字幕国产精品一区二区三区 | 欧美人与性动交α欧美软件| 女人被躁到高潮嗷嗷叫费观| 欧美变态另类bdsm刘玥| 亚洲精品粉嫩美女一区| 91国产中文字幕| 欧美精品av麻豆av| 午夜激情av网站| 在线观看免费视频网站a站| 中文字幕人妻丝袜一区二区| 中国美女看黄片| 99久久精品国产亚洲精品| 亚洲色图综合在线观看| 精品国产超薄肉色丝袜足j| 考比视频在线观看| 欧美激情高清一区二区三区| 亚洲人成伊人成综合网2020| 久久久久精品国产欧美久久久| 中文字幕精品免费在线观看视频| 悠悠久久av| 国产一区二区三区视频了| svipshipincom国产片| 久热爱精品视频在线9| 国产不卡av网站在线观看| 亚洲专区中文字幕在线| 激情视频va一区二区三区| 精品久久久精品久久久| 国产国语露脸激情在线看| 在线观看免费视频日本深夜| 黄色怎么调成土黄色| 国产极品粉嫩免费观看在线| 啦啦啦免费观看视频1| 黄色怎么调成土黄色| 精品国产一区二区三区久久久樱花| 丁香六月天网| 免费在线观看影片大全网站| 大陆偷拍与自拍| 国产又色又爽无遮挡免费看| 亚洲欧美日韩另类电影网站| 搡老乐熟女国产| 午夜久久久在线观看| 黄色视频,在线免费观看| 亚洲va日本ⅴa欧美va伊人久久| 亚洲精品乱久久久久久| 精品视频人人做人人爽| 99久久99久久久精品蜜桃| 午夜福利欧美成人| 丝袜在线中文字幕| 亚洲国产欧美网| a在线观看视频网站| 久久精品国产亚洲av高清一级| 中文字幕人妻丝袜制服| 2018国产大陆天天弄谢| 久久午夜亚洲精品久久| 视频在线观看一区二区三区| 在线看a的网站| a级毛片在线看网站| 十八禁网站免费在线| 日日摸夜夜添夜夜添小说| 美国免费a级毛片| 美女视频免费永久观看网站| 涩涩av久久男人的天堂| 天天躁狠狠躁夜夜躁狠狠躁| 国产精品久久久人人做人人爽| 久久久国产精品麻豆| 露出奶头的视频| 在线看a的网站| 欧美精品av麻豆av| 性色av乱码一区二区三区2| 男女免费视频国产| 日韩人妻精品一区2区三区| 亚洲欧美一区二区三区黑人| 国产福利在线免费观看视频| 18禁黄网站禁片午夜丰满| 久久影院123| 久久人人爽av亚洲精品天堂| 蜜桃在线观看..| 丝袜喷水一区| 久热这里只有精品99| 久久久水蜜桃国产精品网| 欧美精品一区二区免费开放| 中国美女看黄片| av福利片在线| 99久久国产精品久久久| 欧美+亚洲+日韩+国产| 日韩免费高清中文字幕av| 亚洲 国产 在线| 日韩欧美三级三区| 亚洲一区二区三区欧美精品| 在线av久久热| 国产99久久九九免费精品| 无限看片的www在线观看| 国产成+人综合+亚洲专区| 女同久久另类99精品国产91| 成人特级黄色片久久久久久久 | 亚洲第一欧美日韩一区二区三区 | 国产精品一区二区免费欧美| 亚洲精品av麻豆狂野| 欧美激情久久久久久爽电影 | 婷婷丁香在线五月| 精品一区二区三区四区五区乱码| 三级毛片av免费| 一进一出抽搐动态| 三级毛片av免费| 国产成人av教育| 欧美黄色淫秽网站| 狂野欧美激情性xxxx| 菩萨蛮人人尽说江南好唐韦庄| 午夜免费成人在线视频| 黄色 视频免费看| 女人高潮潮喷娇喘18禁视频| 这个男人来自地球电影免费观看| 国内毛片毛片毛片毛片毛片| 性高湖久久久久久久久免费观看| 国产午夜精品久久久久久| 欧美日韩中文字幕国产精品一区二区三区 | 国产一区二区三区在线臀色熟女 | 多毛熟女@视频| 色综合欧美亚洲国产小说| 18禁裸乳无遮挡动漫免费视频| 在线av久久热| 亚洲国产中文字幕在线视频| 十分钟在线观看高清视频www| av片东京热男人的天堂| 久久ye,这里只有精品| 国产精品久久久久成人av| 精品福利观看| 亚洲av成人一区二区三| 王馨瑶露胸无遮挡在线观看| √禁漫天堂资源中文www| 国产成人一区二区三区免费视频网站| 露出奶头的视频| 久久人妻福利社区极品人妻图片| videosex国产| 视频区欧美日本亚洲| 国产精品 国内视频| 一本色道久久久久久精品综合| 亚洲av成人一区二区三| 少妇粗大呻吟视频| 考比视频在线观看| 久久亚洲真实| 国产成人欧美| 男女边摸边吃奶| 国产色视频综合| 国产精品欧美亚洲77777| 色尼玛亚洲综合影院| 国产在线精品亚洲第一网站| 咕卡用的链子| 黄色 视频免费看| av欧美777| 丝袜美腿诱惑在线| 欧美精品人与动牲交sv欧美| 欧美黄色淫秽网站| 国产亚洲精品一区二区www | 最新在线观看一区二区三区| 国产极品粉嫩免费观看在线| 亚洲国产欧美在线一区| 91老司机精品| 国产精品久久久久久精品电影小说| 久久狼人影院| 国产精品久久久久久人妻精品电影 | 一级毛片女人18水好多| 我要看黄色一级片免费的| 国产精品久久久久久精品电影小说| 日本黄色视频三级网站网址 | 精品少妇一区二区三区视频日本电影| 成人特级黄色片久久久久久久 | 国产不卡一卡二| 黄片小视频在线播放| 51午夜福利影视在线观看| 亚洲欧美一区二区三区黑人| 高清毛片免费观看视频网站 | 黑人猛操日本美女一级片| 国产精品欧美亚洲77777| 国精品久久久久久国模美| 久久婷婷成人综合色麻豆| 成年动漫av网址| a级毛片在线看网站| 日本av手机在线免费观看| 亚洲精品在线美女| 老汉色av国产亚洲站长工具| 亚洲人成电影观看| 天堂8中文在线网| 亚洲国产欧美日韩在线播放| 欧美日本中文国产一区发布| 日本av免费视频播放| 日本av手机在线免费观看| 亚洲三区欧美一区| 午夜福利,免费看| 两性夫妻黄色片| 看免费av毛片| 免费在线观看影片大全网站| 国产欧美亚洲国产| 久久天堂一区二区三区四区| 麻豆国产av国片精品| 人人妻人人添人人爽欧美一区卜| 欧美成人午夜精品| 久久中文看片网| 国产精品 国内视频| av网站在线播放免费| 欧美精品啪啪一区二区三区| 欧美午夜高清在线| av福利片在线| 王馨瑶露胸无遮挡在线观看| 午夜福利视频在线观看免费| 黄频高清免费视频| 精品午夜福利视频在线观看一区 | 国产视频一区二区在线看| 久久久精品免费免费高清| 久久精品亚洲av国产电影网| 两个人看的免费小视频| 九色亚洲精品在线播放| 久久精品aⅴ一区二区三区四区| 亚洲一码二码三码区别大吗| 最新在线观看一区二区三区| 久久精品国产综合久久久| 日本五十路高清| 国产精品av久久久久免费| 国产97色在线日韩免费| 欧美 亚洲 国产 日韩一| 亚洲av美国av| 国产麻豆69| 国产精品98久久久久久宅男小说| 美女高潮到喷水免费观看| 少妇的丰满在线观看| 激情在线观看视频在线高清 | 国产精品一区二区精品视频观看| 一进一出好大好爽视频| 久久亚洲真实| 成人18禁在线播放| 黄色视频在线播放观看不卡| 欧美黑人欧美精品刺激| 国产精品秋霞免费鲁丝片| 亚洲国产欧美网| 亚洲 国产 在线| 大陆偷拍与自拍| 18禁黄网站禁片午夜丰满| 丝袜美足系列| 日韩视频在线欧美| 中文欧美无线码| 色视频在线一区二区三区| 日韩成人在线观看一区二区三区| 色94色欧美一区二区| 久久性视频一级片| 两人在一起打扑克的视频| 一区二区三区国产精品乱码| 丝袜在线中文字幕| 成年人免费黄色播放视频| 三级毛片av免费| 一区二区三区乱码不卡18| 丝瓜视频免费看黄片| 成人av一区二区三区在线看| 国产精品二区激情视频| 一区二区av电影网| 在线观看66精品国产| 国产一区二区激情短视频| 久久久国产一区二区| 国产高清视频在线播放一区| 亚洲av第一区精品v没综合| 看免费av毛片| h视频一区二区三区| 亚洲国产av新网站| 黑人巨大精品欧美一区二区mp4| 国产一区二区三区在线臀色熟女 | 一二三四社区在线视频社区8| 婷婷丁香在线五月| 亚洲全国av大片| 这个男人来自地球电影免费观看| 夜夜骑夜夜射夜夜干| 亚洲久久久国产精品| 大片电影免费在线观看免费| 韩国精品一区二区三区| 成年人黄色毛片网站| 黄色成人免费大全| 免费女性裸体啪啪无遮挡网站| 国产99久久九九免费精品| 热99久久久久精品小说推荐| 91大片在线观看| 国产伦理片在线播放av一区| 啦啦啦在线免费观看视频4| 国产精品.久久久| 99久久99久久久精品蜜桃| 亚洲九九香蕉| 在线 av 中文字幕| 丝袜人妻中文字幕| 婷婷成人精品国产| 亚洲人成电影免费在线| 国产日韩欧美亚洲二区| 国产精品秋霞免费鲁丝片| 成人国产一区最新在线观看| 一本—道久久a久久精品蜜桃钙片| 一个人免费看片子| 人妻久久中文字幕网| 两个人免费观看高清视频| 国产aⅴ精品一区二区三区波| 99精品欧美一区二区三区四区| 久久青草综合色| 成人亚洲精品一区在线观看| 我要看黄色一级片免费的| 国产亚洲午夜精品一区二区久久| 久久中文看片网| 亚洲精品久久午夜乱码| 老司机影院毛片| 国产精品久久久久成人av| 人成视频在线观看免费观看| 丰满饥渴人妻一区二区三| 国产熟女午夜一区二区三区| 精品亚洲乱码少妇综合久久| 欧美人与性动交α欧美精品济南到| 午夜两性在线视频| 日韩有码中文字幕| 久久久国产欧美日韩av| 国产精品 欧美亚洲| 亚洲成人免费av在线播放| 日本一区二区免费在线视频| 亚洲少妇的诱惑av| 亚洲精品国产一区二区精华液| 天天影视国产精品| 亚洲天堂av无毛| 黑人巨大精品欧美一区二区mp4| 大香蕉久久成人网| www.自偷自拍.com| 一级片'在线观看视频| 国产精品国产av在线观看| 午夜免费鲁丝| 叶爱在线成人免费视频播放| 国产精品98久久久久久宅男小说| 波多野结衣一区麻豆| 久久久欧美国产精品| 高潮久久久久久久久久久不卡| 国产成人精品在线电影| 五月天丁香电影| 高清毛片免费观看视频网站 | 啦啦啦中文免费视频观看日本| 日韩视频一区二区在线观看| 午夜激情av网站| 成年人黄色毛片网站| 亚洲av成人不卡在线观看播放网| 老司机午夜福利在线观看视频 | 国产成人欧美在线观看 | 一边摸一边抽搐一进一小说 | 亚洲精品国产精品久久久不卡| 欧美日韩国产mv在线观看视频| 久久久久久久精品吃奶| 妹子高潮喷水视频| e午夜精品久久久久久久| 久久亚洲精品不卡| 日日夜夜操网爽| 91av网站免费观看| 国产视频一区二区在线看| 精品国产乱码久久久久久小说| 亚洲成人免费av在线播放| 久久久精品94久久精品| 国产精品九九99| 中文字幕精品免费在线观看视频| 又大又爽又粗| 久久人人97超碰香蕉20202| 精品午夜福利视频在线观看一区 | 熟女少妇亚洲综合色aaa.| 久久中文看片网| 热re99久久国产66热| 18禁美女被吸乳视频| 中文亚洲av片在线观看爽 | 免费一级毛片在线播放高清视频 | 建设人人有责人人尽责人人享有的| 国产极品粉嫩免费观看在线| 亚洲国产看品久久| 一级毛片女人18水好多| 性色av乱码一区二区三区2| 在线观看免费视频日本深夜| 黄色片一级片一级黄色片| 日韩 欧美 亚洲 中文字幕| 黄片播放在线免费| 久久中文字幕人妻熟女| 一边摸一边做爽爽视频免费| 极品人妻少妇av视频| 国产高清激情床上av| 国产精品一区二区免费欧美| 成在线人永久免费视频| 亚洲精品一卡2卡三卡4卡5卡| 午夜精品久久久久久毛片777| 国产成人系列免费观看| 淫妇啪啪啪对白视频| 香蕉丝袜av| 中文亚洲av片在线观看爽 | 丰满少妇做爰视频| 久久久久国内视频| 99久久人妻综合| 一级毛片电影观看| 国产成人精品在线电影| 亚洲欧美精品综合一区二区三区| 18禁黄网站禁片午夜丰满| 久久精品熟女亚洲av麻豆精品| 看免费av毛片| 99国产精品一区二区蜜桃av | 捣出白浆h1v1| 新久久久久国产一级毛片| www.熟女人妻精品国产| 露出奶头的视频| 亚洲欧美精品综合一区二区三区| 热99re8久久精品国产| 日日夜夜操网爽| 亚洲av日韩在线播放| 免费在线观看影片大全网站| 欧美成人免费av一区二区三区 | 欧美日韩亚洲综合一区二区三区_| 亚洲精品一卡2卡三卡4卡5卡| 黄色片一级片一级黄色片| 国产主播在线观看一区二区| 成人精品一区二区免费| 一级片免费观看大全| 中文字幕制服av| 国产男女内射视频| 亚洲男人天堂网一区| 日日夜夜操网爽| 国产精品一区二区在线观看99| 国产精品国产高清国产av | 亚洲人成伊人成综合网2020| 久久久精品免费免费高清| 国产aⅴ精品一区二区三区波| 男女床上黄色一级片免费看| 欧美日韩国产mv在线观看视频| 日韩大码丰满熟妇| 国产野战对白在线观看| 久久影院123| 精品国产乱码久久久久久男人| 黄网站色视频无遮挡免费观看| 日韩大片免费观看网站| 美女高潮喷水抽搐中文字幕| 不卡av一区二区三区| 国产欧美日韩一区二区精品| 色在线成人网| 国产aⅴ精品一区二区三区波| 香蕉丝袜av| 婷婷成人精品国产| 久久久国产一区二区| 国产精品九九99| 一级a爱视频在线免费观看| 亚洲人成伊人成综合网2020| 亚洲第一青青草原| 不卡av一区二区三区| 别揉我奶头~嗯~啊~动态视频| 亚洲精品久久成人aⅴ小说| 久久国产亚洲av麻豆专区| 一级,二级,三级黄色视频| 十八禁高潮呻吟视频| 黄片播放在线免费| 国产成人精品久久二区二区91| 狠狠精品人妻久久久久久综合| 丰满人妻熟妇乱又伦精品不卡| 99精国产麻豆久久婷婷| 超碰97精品在线观看| 2018国产大陆天天弄谢| 国产午夜精品久久久久久| 国产精品1区2区在线观看. | 国产精品欧美亚洲77777| 国产一区二区三区在线臀色熟女 | 在线 av 中文字幕| 黄色片一级片一级黄色片| 久久天堂一区二区三区四区| 夜夜骑夜夜射夜夜干| 午夜精品久久久久久毛片777| 精品人妻在线不人妻| 亚洲av成人一区二区三| 久久九九热精品免费| 巨乳人妻的诱惑在线观看| 99国产精品99久久久久| 18在线观看网站| 免费日韩欧美在线观看| 69av精品久久久久久 | 亚洲综合色网址| 久久精品人人爽人人爽视色| 亚洲欧美激情在线| 91麻豆av在线| 国产三级黄色录像| 亚洲成人免费电影在线观看| 777米奇影视久久|